Complete trial results of Novavax COVID-19 investigational vaccine posted to preprint server medRxiv
On May 21, 2021, Novavax announced that the full results from the Phase 3, randomized, observer-blinded, placebo-controlled trial…
On May 21, 2021, Novavax announced that the full results from the Phase 3, randomized, observer-blinded, placebo-controlled trial…
On May 21, 2021, Novavax announced participation in a mix-and-match (vaccine interchangeability) COVID-19 vaccine booster trial that led…
On May 21, 2021, Gavi, the Vaccine Alliance, that it had signed an advance purchase agreement with Johnson…
On May 20, 2021, Merck announced V114, the company�s investigational 15-valent pneumococcal conjugate vaccine, met its primary immunogenicity…
On May 20, 2021, Pfizer and BioNTech announced a new agreement with the European Commission (EC) to supply…
On May 20, 2021, Pfizer and BioNTech announced an agreement with Turkeyï¾’s Ministry of Health to supply 60…
On May 18, 2021, GlaxoSmithKline and Medicago reported positive interim Phase 2 clinical trial safety and immunogenicity data…
On May 17, 2021, Oxford University and Oracle announced they had created a Global Pathogen Analysis System combining…
On May 17, 2021, Sanofi and GSK reported that their adjuvanted recombinant COVID-19 vaccine candidate achieved strong rates…
On May 13, 2021, CureVac announced together with its collaboration partner GSK, first preclinical data in a rat…
On May 13, 2021, University of Oxford researchers reported that Com-COV study data comparing mixed dosing schedules of…
On May 12, 2021, Moderna announced a new supply agreement with the government of Australia for 25 million…
On May 12, 2021, Inovio Pharma announced that its next-generation Pan-COVID-19 vaccine candidate, INO-4802, induced potent neutralizing antibodies…
On May 10, 2021, Novavax announced data from a preclinical study of the company’s combination quadrivalent seasonal flu…
On May 10, 2021, Inovio Pharma announced positive safety, tolerability and immunogenicity data from its placebo-controlled and blinded…
On May 7, 2021, the World Health Organization (WHO) listed the Sinopharm COVID-19 vaccine for emergency use, giving…
On May 7, 2021, Pfizer and BioNTech announced the initiation of a Biologics License Application (BLA) with the…
On May 6, 2021, Moderna announced a new supply agreement with the Swiss Federal Government for 7 million…
On May 6, 2021, Novavax announced that it had finalized an advance purchase agreement (APA) with Gavi, the…
On May 5, 2021, Novavax announced the publication of results from the initial primary analysis of a Phase…
On May 5, 2021, Pfizer and BioNTech announced that Health Canada had expanded the Interim Order authorization for…
On May 4, 2021, Moderna announced an expansion of the Moderna Technology Center (MTC) in Norwood, MA including…
On May 4, 2021, HDT Bio announced that its development partner in India, Gennova Biopharmaceuticals, had begun dosing…
On May 3, 2021, the World Health Organization (WHO) welcomed the Government of Swedenï¾’s announcement to share 1…
On May 3, 2021, Vaxart announced that new data obtained from its Phase I COVID-19 trial added to…
On May 3, 2021, Moderna announced an agreement with Gavi, the Vaccine Alliance to supply up to 500…
On May 3, 2021, Novavax announced that it had initiated a pediatric expansion of its Phase 3 clinical…
On May 3, 2021, Gavi, the Vaccine Alliance, that it had signed an advance purchase agreement with Moderna…
On Apr. 30, 2021, Moderna announced that the World Health Organization (WHO) had issued Emergency Use Listing (EUL)…
On Apr. 29, 2021, Lonza announced the expansion of its collaboration with Moderna to manufacture the drug substance…